Schematic of Drug Development Pipeline. Phage display in humans or with cultured tumor cells identified common and/or unique receptors that can be exploited for targeted drug delivery. In the case of BMTP-11 or myristoylated BMTP-11, the targeting peptide ligand, CGRRAGGSC, was synthetically fused to the apoptotic peptide, D(KLAKKLAK)2, and validated in vivo and in vitro, respectively. BMTP-11 was advanced to preclinical studies, and following FDA approval, BMTP-11 was tested as a new investigational drug in a first-in-man clinical trial.